Buffington Mohr McNeal lifted its position in Teleflex Incorporated (NYSE:TFX) by 7.0% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 10,010 shares of the medical technology company’s stock after buying an additional 655 shares during the quarter. Buffington Mohr McNeal’s holdings in Teleflex were worth $2,430,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Toronto Dominion Bank grew its stake in shares of Teleflex by 14.5% in the 2nd quarter. Toronto Dominion Bank now owns 552 shares of the medical technology company’s stock valued at $115,000 after buying an additional 70 shares in the last quarter. Advisory Services Network LLC grew its stake in shares of Teleflex by 933.8% in the 2nd quarter. Advisory Services Network LLC now owns 827 shares of the medical technology company’s stock valued at $172,000 after buying an additional 747 shares in the last quarter. Cornerstone Capital Management Holdings LLC. bought a new stake in shares of Teleflex in the 2nd quarter valued at approximately $175,000. OLD Mutual Customised Solutions Proprietary Ltd. grew its stake in shares of Teleflex by 200.0% in the 1st quarter. OLD Mutual Customised Solutions Proprietary Ltd. now owns 900 shares of the medical technology company’s stock valued at $174,000 after buying an additional 600 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC bought a new stake in shares of Teleflex in the 2nd quarter valued at approximately $200,000. 89.78% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This story was published by Watch List News and is the property of of Watch List News. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.watchlistnews.com/buffington-mohr-mcneal-purchases-655-shares-of-teleflex-incorporated-tfx/1673636.html.

In other Teleflex news, Director Stephen K. M.D. Klasko sold 200 shares of Teleflex stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $241.88, for a total value of $48,376.00. Following the completion of the transaction, the director now directly owns 8,080 shares of the company’s stock, valued at approximately $1,954,390.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.39% of the stock is owned by insiders.

Teleflex (NYSE:TFX) last announced its quarterly earnings data on Thursday, November 2nd. The medical technology company reported $2.12 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.00 by $0.12. The firm had revenue of $534.70 million during the quarter, compared to analysts’ expectations of $522.94 million. Teleflex had a return on equity of 16.12% and a net margin of 12.36%. The company’s quarterly revenue was up 17.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.80 EPS.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 15th. Shareholders of record on Wednesday, November 15th will be issued a $0.34 dividend. This represents a $1.36 annualized dividend and a yield of 0.57%. Teleflex’s dividend payout ratio is presently 26.00%.

A number of brokerages have issued reports on TFX. Leerink Swann raised Teleflex from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $227.00 to $266.00 in a research report on Thursday, September 7th. Zacks Investment Research lowered Teleflex from a “buy” rating to a “hold” rating in a report on Thursday, August 31st. Jefferies Group LLC reiterated a “buy” rating and set a $230.00 price target on shares of Teleflex in a report on Thursday, August 3rd. KeyCorp reiterated a “hold” rating on shares of Teleflex in a report on Wednesday, September 6th. Finally, BidaskClub lowered Teleflex from a “buy” rating to a “hold” rating in a report on Monday, July 31st. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $260.75.

About Teleflex

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Want to see what other hedge funds are holding TFX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teleflex Incorporated (NYSE:TFX).

Institutional Ownership by Quarter for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.